PharmX Technologies Limited (ASX:PHX)

Australia · Delayed Price · Currency is AUD

0.0980

0.00 (0.00%)

Apr 29, 2026, 2:09 PM AEST

28.95% (1Y)

Market Cap	64.63M
Revenue (ttm)	7.65M
Net Income (ttm)	-931.00K
Shares Out	659.46M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	132,383
Average Volume	250,779
Open	0.0980
Previous Close	0.0980
Day's Range	0.0980 - 0.0980
52-Week Range	0.0730 - 0.2000
Beta	0.39
RSI	38.40
Earnings Date	Feb 24, 2026

About PharmX Technologies

PharmX Technologies Limited, together with its subsidiaries, operates as a technology and software development company in Australia. It also operates PharmX, an electronic ordering and invoicing gateway; PharmX Marketplace, an e-commerce ordering platform; PharmX Analytics which provides insights for operations of supplier and pharmacy customers. The company was formerly known as Corum Group Limited and changed its name to PharmX Technologies Limited in October 2023. PharmX Technologies Limited was incorporated in 1950 and is headquartered in S... [Read more]

Industry Health Information Services

Sector Healthcare

Founded 1950

Employees 109

Stock Exchange Australian Securities Exchange

Ticker Symbol PHX

Full Company Profile

Financial Performance

In fiscal year 2025, PharmX Technologies's revenue was 7.53 million, a decrease of -6.97% compared to the previous year's 8.09 million. Losses were -264,000, -85.08% less than in 2024.

Financial Statements

News

PharmX Technologies Earnings Call Transcript: H1 2026

Revenue grew 3% to AUD 3.9 million with strong Marketplace and New Zealand performance, positive EBITDA, and a major strategic partnership with Sigma Chemist Warehouse. Marketplace adoption and supplier integration surged, supporting future growth.

2 months ago - Transcripts

PharmX Technologies Earnings Call Transcript: H2 2025

FY 2025 delivered 13% revenue growth, strong platform expansion, and improved cash flow, despite higher investment. Marketplace and AI-driven initiatives are set to drive FY 2026 growth, with a stable cost base and robust market position.

9 months ago - Transcripts

PharmX Technologies Earnings Call Transcript: H1 2025

Revenue grew 17% year-over-year, driven by strong performance in core and marketplace platforms, expansion into New Zealand, and new analytics offerings. Despite higher investment and a major legal settlement, profitability improved and the cash position remains strong.

1 year ago - Transcripts